E2F1 transcription factor

Shimizu S, Khan MZ, Hippensteel RL, Parkar A, Raghupathi R, Meucci O (2007) Role of the transcription factor E2F1 in CXCR4-mediated neurotoxicity and HIV neuropathology. Neurobiol Dis 25 17-26... 

Cooper-Kuhn CM, Vroemen M, Brown J, Ye H, Thompson MA, et al. 2002. Impaired adult neurogenesis in mice lacking the transcription factor E2F1. Mol Cell Neurosci 21 312-323. 

The cyclin A-CDK2 complex has been shown to phosphorylate, among others, the transcription factor E2F1 and components of the DNA replication complex. 

IkB-q (inhibitor of transcription factor NF-kB)), proteins that regulate cellular adaptation to hypoxic stress (i.e., HIF-lct), and proteins related to aberrant gene expression in tumors (e.g., c-Jun, /3-catenin, IttB-a, E2F1). Proteasome inhibitors are under development as new antitumor chemotherapeutic agents and the proteasome inhibitor bortezomib (PS-341, Velcade) has been approved by the U.S. Food and Drug Administration (FDA). 

M.L., and Leone, G., The E2F1-3 transcription factors are essential for cellular proliferation, Nature, 414, 457-N62, 2001. 

Johnson, D.G., Schwarz, J.K., Cress, W.D., and Nevins, J.R., Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature, 365, 349-352, 1993. 

---